

Konstantynów Łódzki, April 6, 2023

Press Release

Mabion expands collaboration with Novavax for vaccine antigen for COVID-19 variant Omicron

- On April 6, 2023, Mabion entered into Amendment No. 2 to the *Statement of Work (SOW)* No. 1 of its agreement with Novavax, which governs activities to add another product to the scope of the collaboration, a vaccine antigen for COVID-19 based on the Omicron variant
- Mabion has completed the technology transfer process for manufacturing an active substance based on the Omicron variant and is in the process of completing process validation, which means that Mabion will have the opportunity to manufacture another Novavax product as part of the collaboration
- The number of Omicron product batches ordered by Novavax will be agreed on an ongoing basis, and will be manufactured within the *Manufacturing Slots* guaranteed to Novavax
- Since the start of its partnership with Novavax in October 2021, Mabion has concluded 10 additional orders, confirming the company's effectiveness in monetizing the high competence it has built over the years

"The concluded annex regarding Novavax's ability to commission another product, which is the vaccine antigen for COVID-19 variant Omicron, is the realization of the measures we announced in September 2022. We are pleased not only with the rapid pace at which Mabion has achieved readiness to handle orders for the new product, but also with the uninterrupted trust that the US partner has in us. This confirms the desire for long-term cooperation on both sides, and gives us another opportunity to gain valuable references, which are of great importance for the customer diversification activities we are actively conducting." -comments **Adam Pietruszkiewicz, Member of the Management Board of Mabion S.A. for Sales.**

Mabion has confirmed its ability to move quickly and efficiently on new product launches and, as announced, it will be able to manufacture the antigen for the vaccine for COVID-19 variant Omicron on behalf of Novavax. The process will include manufacturing, conducting analytical testing of product samples, stability studies, sourcing raw materials for production, quality management and supervision, and supporting Novavax in meeting registration requirements. The full range of manufacturing and analytical activities involved in producing the vaccine antigen for COVID-19 in the Omicron variant, will take place under GMP (*Good Manufacturing Practice*) standards.

"Mabion's processes and activities on the Mabion side, related to the contract manufacturing of the antigen for the vaccine for COVID-19 variant Omicron, are in line with the expectations and needs of many global biopharmaceutical companies. Thus, a wide range of services including, among others, manufacturing, comprehensive analytics of intermediates as well as finished products, long-term stability studies or quality management and supervision are activities that we can also provide to other customers. For the entire team, a particular reason for satisfaction is the short time from Novavax's request to the implementation of a new process to full scale in a GMP environment with all accompanying activities such as analytics and quality supervision. This would not have been possible without the Company's well laid out processes in the Company and qualified personnel, which confirms the high competence built at Mabion," says **Slawomir Jaros, Mabion S.A. Board Member for Operations and Scientific Affairs.**

"According to the agreement, the quantity of Omicron product batches commissioned for manufacturing will be agreed upon by the parties on an ongoing basis and will be within the framework of Mabion's production capacity guaranteed to Novavax to date, under the formula of payment for batches manufactured or for readiness to manufacture the product. This developed formula of cooperation is important from the point of view of predictability of our operating flows and stabilization of our liquidity position," - **Grzegorz Grabowicz, Member of the Management Board for Finance of Mabion S.A., adds.**

Until 2021, the Company focused on developing its portfolio of proprietary biological products. With the agreement with the US entity Novavax in October 2021, Mabion successfully began to commercialize the competencies it had built and initiated the transformation into a fully integrated GLP and GMP certified biopharmaceutical company with CDMO services in the form of analytics and contract manufacturing, among others. The successful execution of the Novavax agreement

worth \$372 million has been extended until the end of 2026 as a result of annexes concluded in September 2022, with guaranteed revenue levels until at least the second quarter of 2024. In addition, the annexes expanded Mabion's remuneration principles with another component - the Company will receive remuneration for the manufactured product series or remuneration for the readiness to manufacture the product (capacity reservation) under the annexes.

Contact for media and individual investors

Michał Wierzchowski

+48 531 613 067

+48 22 440 14 40

michal.wierzchowski@ccgroup.pl

Mardoniusz Maćkowiak

+48 605 959 539

+48 22 440 14 40

mardoniusz.mackowiak@ccgroup.pl

Contact for institutional investors and analysts

Piotr Owdziej

+48 697 612 913

+48 22 440 14 40

piotr.owdziej@ccgroup.pl

Katarzyna Mucha

+48 697 613 712

+48 22 440 14 40

katarzyna.mucha@ccgroup.pl

Information about Mabion S.A.

Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organization (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early stage discovery to commercial manufacturing). Mabion's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the vaccine for COVID-19, which it has since steadily expanded through further services under SOWs (Statements of Work) concluded and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. According to the Strategy, announced in April 2023, the Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete Mabion's full transformation into an integrated biologics CDMO company. Mabion is a public Company, listed on the Warsaw Stock Exchange.

For more information about the Company, visit www.mabion.eu